AusperBio Secures $50 Million Series B+ Funding to Advance Hepatitis B Functional Cure Candidate AHB-137
核心洞察
AusperBio completed an oversubscribed $50 million Series B+ financing round led by existing investors with participation from major venture capital firms.
The funding will support ongoing clinical development of AHB-137, a novel antisense oligonucleotide targeting chronic hepatitis B (搜索), including planned Phase II trials outside mainland China.
AHB-137 has shown positive Phase IIb data presented at EASL Congress and has completed global Phase 1b trials while advancing through multiple Phase 2 studies in China.
AusperBio Therapeutics (搜索) has secured $50 million in Series B+ funding to advance its lead hepatitis B treatment candidate through global clinical development. The oversubscribed financing round was led by an existing industry-leading venture capital investor, with strong participation from Qiming Venture Partners (搜索), CDH Investments (搜索), Genesis Capital (搜索), YuanBio Venture Capital (搜索), HanKang Capital (搜索), and Sherpa Capital (搜索).
The clinical-stage biotechnology company, which operates in both the United States and China, announced the completion of the funding round on May 28, 2025. This latest financing follows the company's Series B round completed in December 2024, demonstrating continued investor confidence in AusperBio's strategic direction and proprietary platform technology.
AHB-137 Clinical Progress and Development Strategy
The proceeds will primarily support the ongoing clinical development of AHB-137, a novel unconjugated antisense oligonucleotide designed to achieve a functional cure for chronic hepatitis B (搜索). The funding will enable planned Phase II trials outside of mainland China, representing a significant expansion of the drug's global development strategy.
AHB-137 is built on AusperBio's proprietary Med-Oligo™ ASO technology platform and functions through a dual-mechanism approach. The treatment has generated compelling clinical data, with key preclinical and clinical results presented at leading medical conferences including EASL (2023, 2024, 2025) and AASLD (2024).
Dr. Chris Yang, co-founder and Chief Scientific Officer, highlighted the recent clinical progress: "We are strongly encouraged by the recent progress of AHB-137, particularly the positive Phase IIb data presented at the EASL Congress in Amsterdam."
The drug candidate has completed its global Phase 1b trial and is currently advancing through multiple Phase 2 studies in China. This dual-track development approach positions AHB-137 for potential regulatory submissions in multiple markets.
Manufacturing Scale-Up and Pipeline Expansion
Beyond clinical development, the new funding will enable AusperBio to scale up commercial manufacturing partnerships, preparing for potential future commercialization. The investment will also support the company's long-term pipeline growth as it leverages its Med-Oligo™ platform for additional therapeutic applications.
Dr. Guofeng Cheng, co-founder and CEO, emphasized the company's commitment to its mission: "This new funding gives us the momentum to move AHB-137 into the next phase of global development. We are committed to stay focused on our mission to deliver a functional cure for chronic hepatitis B (搜索) and bring life-changing therapies to patients worldwide."
Platform Technology and Therapeutic Potential
AusperBio's proprietary Med-Oligo™ ASO platform has been designed to substantially enhance current antisense oligonucleotide therapeutics through novel insights into ASO design. The platform combines efficient targeted delivery conjugation technologies, creating a modular system that empowers ASO therapeutics to treat a broad range of diseases beyond hepatitis B, including viral infections, metabolic conditions, genetic disorders, and immune diseases.
The company's focus on achieving a functional cure for chronic hepatitis B (搜索) addresses a significant unmet medical need. AusperBio aims to alleviate the global health burden of chronic hepatitis B and transform treatment paradigms for this serious chronic disease through patient-centered innovations.